GBA1 and infection: While expression under the control of the CBh promoter plateaued at the multiplicities of infection (MOI) of 105, AAV9-EFS-GBA1 showed dose-dependent increase of expression in the dose range tested, with the highest dose (MOI of 106) yielding a ~ 2-fold higher GCase level than the CBh group.